BioXcel Therapeutics has launched a pivotal Phase 3 trial program to continue to evaluate BXCL501, its oral experimental candidate for the treatment of agitation in patients with Alzheimer’s disease. The new program consists of two clinical trials — TRANQUILITY II and TRANQUILITY III — and will assess the safety and efficacy of BXCL501 in adults ages 65 and older in assisted living or residential facilities and nursing homes. “This marks an important advancement in potentially…
You must be logged in to read/download the full post.
The post Phase 3 Program Will Continue to Assess BXCL501 to Treat Agitation appeared first on BioNewsFeeds.